Literature DB >> 10745023

Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium.

S I Ahmed1, J Thompson, J M Coulson, P J Woll.   

Abstract

Lung cancer, particularly small cell lung cancer (SCLC), is characterized by production of numerous peptides and their resulting clinical syndromes. Such peptides can act as autocrine growth factors for these tumors. In this study, we investigated the role of endothelin (ET)-1 in lung cancer. Using reverse transcription/polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay, and immunocytochemistry, we screened a panel of lung cancer cell lines for ET-1, its receptors, and endothelin converting enzyme-1 (ECE-1), which generates the active form of ET-1. ET-1 messenger RNA was expressed in five of seven SCLC, four of four non-small cell lung cancer (NSCLC), and human bronchial epithelial (HBE) cells. The intracellular isoform of ECE-1, important in processing ET-1 if an autocrine growth loop is to function, was downregulated in the lung cancer cell lines as compared with expression of the extracellular isoform. Endothelin A receptor (ETAR), which mediates the mitogenic effects of ET-1 in prostate and ovarian cancer, was upregulated in HBE cells compared with expression in three of seven SCLC and two of four NSCLC cell lines. Endothelin B receptor (ETBR) was more widespread, being expressed in seven of seven SCLC, four of four NSCLC, and the HBE cells. We used flow cytometry to measure mobilization of intracellular calcium as a functional assay for the ETAR. These data concurred with the RT-PCR results, indicating that the ETAR was downregulated or was involved in an alternative signal transduction pathway in lung cancer, and no evidence of functional receptor mediating an autocrine growth loop was found. From our study, the data do not support the putative functional autocrine growth role of ET-1 in lung cancer. We propose instead that ET-1 may act as a paracrine growth factor for surrounding epithelial and endothelial cells via alternative pathways, promoting angiogenesis and stromal growth.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10745023     DOI: 10.1165/ajrcmb.22.4.3795

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  29 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

2.  Role of endothelin receptor activation in secondary pulmonary hypertension in awake swine after myocardial infarction.

Authors:  Birgit Houweling; Daphne Merkus; Oana Sorop; Frans Boomsma; Dirk J Duncker
Journal:  J Physiol       Date:  2006-05-18       Impact factor: 5.182

3.  Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.

Authors:  Terry W Moody; Irene Ramos-Alvarez; Paula Moreno; Samuel A Mantey; Lisa Ridnour; David Wink; Robert T Jensen
Journal:  Peptides       Date:  2017-01-31       Impact factor: 3.750

Review 4.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

5.  Upstream stimulatory factor activates the vasopressin promoter via multiple motifs, including a non-canonical E-box.

Authors:  Judy M Coulson; Jodie L Edgson; Zoe V Marshall-Jones; Robert Mulgrew; John P Quinn; Penella J Woll
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

6.  Expression of endothelin 1 and its angiogenic role in meningiomas.

Authors:  Laura Boldrini; Sabina Pistolesi; Silvia Gisfredi; Silvia Ursino; Greta Alì; Nicola Pieracci; Fulvio Basolo; Giuliano Parenti; Gabriella Fontanini
Journal:  Virchows Arch       Date:  2006-09-30       Impact factor: 4.064

7.  Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Seok Joong Yun; Junqin He; Emily Brantley; Dominic Fan; Panja Strickner; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

8.  Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1.

Authors:  Raksha Jain; Philip W Shaul; Zea Borok; Brigham C Willis
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-22       Impact factor: 6.914

Review 9.  Role of the endothelin axis and its antagonists in the treatment of cancer.

Authors:  A Bagnato; M Loizidou; B R Pflug; J Curwen; J Growcott
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

10.  Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice.

Authors:  Phuong N Quang; Brian L Schmidt
Journal:  J Pain       Date:  2010-01-13       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.